ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Fomepizole: Drug information

Fomepizole: Drug information
(For additional information see "Fomepizole: Pediatric drug information" and see "Fomepizole: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • Antizol
Pharmacologic Category
  • Antidote
Dosing: Adult
Acetaminophen overdose, adjunctive agent

Acetaminophen overdose, adjunctive agent:

Note: Consultation with a clinical toxicologist or poison control center is highly recommended to determine if fomepizole therapy is indicated; routine use is not recommended (Ref). Dosing is based on use in ethylene glycol and methanol toxicity, as well as preclinical data in healthy volunteers who received supratherapeutic doses of acetaminophen (Ref).

IV: Limited data available: 15 mg/kg, followed by 10 mg/kg every 12 hours as needed. A single loading dose is often described in case reports; however, additional doses may be reasonable based on patient presentation and severity (Ref). The duration of therapy should be determined in consultation with a clinical toxicologist or poison control center (Ref).

Ethylene glycol or methanol toxicity

Ethylene glycol or methanol toxicity:

Note: Fomepizole therapy should begin immediately upon suspicion of ethylene glycol or methanol ingestion. Consultation with a clinical toxicologist or poison control center is highly recommended to determine if fomepizole therapy is indicated.

IV: 15 mg/kg (loading dose), followed by doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours until ethylene glycol or methanol concentrations have been reduced to <20 mg/dL and patient is asymptomatic with normal pH. Note: For severe toxicity requiring concomitant hemodialysis, see dosage adjustment in altered kidney function.

Dosing: Kidney Impairment: Adult

Note: Hemodialysis should be considered as an adjunct to fomepizole in patients with kidney failure, significant or worsening metabolic acidosis, or ethylene glycol or methanol concentrations ≥50 mg/dL (Ref). The following dosing adjustments should be used for any patient receiving hemodialysis regardless of kidney function.

Prior to the start of hemodialysis:

To determine if the patient requires a dose of fomepizole at the start of hemodialysis, determine when the last dose was administered.

If the last dose of fomepizole was given <6 hours ago, do not administer another dose upon beginning hemodialysis.

If the last dose of fomepizole was given ≥6 hours ago, administer next scheduled dose upon beginning hemodialysis.

During hemodialysis:

Intermittent hemodialysis: During intermittent hemodialysis, administer fomepizole every 4 hours. Alternatively, a continuous IV infusion of 1 mg/kg/hour may be considered (Ref).

CRRT: During CRRT, administer fomepizole every 8 hours. Alternatively, a continuous IV infusion of 0.5 mg/kg/hour may be considered (Ref).

Upon completion of hemodialysis:

To determine if the patient requires a dose of fomepizole at the time of completion of hemodialysis, determine when the last dose was administered.

If the last dose of fomepizole was given <1 hour ago, do not administer a dose at the end of hemodialysis.

If the last dose of fomepizole was given 1 to 3 hours ago, administer one-half of the next scheduled dose at the end of hemodialysis.

If the last dose of fomepizole was given >3 hours ago, administer the next scheduled dose at the end of hemodialysis.

Maintenance dose when off hemodialysis: Administer fomepizole every 12 hours (starting 12 hours from last dose administered).

Dosing: Hepatic Impairment: Adult

Fomepizole is metabolized in the liver. Specific dosage adjustments have not been determined in patients with hepatic impairment.

Dosing: Older Adult

Specific studies have not been conducted in elderly patients.

Dosing: Pediatric

(For additional information see "Fomepizole: Pediatric drug information")

Note: Fomepizole therapy should begin immediately upon suspicion of ethylene glycol or methanol ingestion. Consultation with a clinical toxicologist or poison control center is highly recommended to determine if fomepizole therapy is indicated.

Ethylene glycol or methanol toxicity; patient not requiring hemodialysis

Ethylene glycol or methanol toxicity; patient not requiring hemodialysis: Limited data available; consider consultation with a clinical toxicology or poison control center:

Infants, Children, and Adolescents: IV: Initial: 15 mg/kg loading dose; followed by 10 mg/kg every 12 hours for 4 doses; then 15 mg/kg every 12 hours until ethylene glycol or methanol concentrations have been reduced to <20 mg/dL and patient is asymptomatic with normal pH (Ref). Note: For severe toxicity requiring concomitant hemodialysis, see "Dosing: Altered Kidney Function: Pediatric."

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents (limited data available) (Ref): Note: Hemodialysis should be considered as an adjunct to fomepizole in patients with renal failure, significant or worsening metabolic acidosis, or ethylene glycol or methanol concentrations ≥50 mg/dL (Ref). The following dosage adjustments should be used for any patient receiving hemodialysis regardless of renal function.

Prior to the start of hemodialysis: To determine if the patient requires a dose of fomepizole at the start of hemodialysis, determine when the last dose was administered.

If <6 hours since last fomepizole dose: Do not administer dose upon beginning dialysis.

If ≥6 hours since last fomepizole dose: Administer next scheduled dose upon beginning dialysis.

During hemodialysis: Administer every 4 hours. Alternatively, a loading dose of 10 to 20 mg/kg followed by a continuous infusion 1 to 1.5 mg/kg/hour during hemodialysis has been described in case reports (Ref).

Upon completion of hemodialysis; dependent upon the time between the last dose and the end of hemodialysis: To determine if the patient requires a dose of fomepizole at the time of completion of hemodialysis, determine when the last dose was administered.

If <1 hour since last fomepizole dose: Do not administer a dose at the end of hemodialysis.

If 1 to 3 hours since last fomepizole dose: Administer 1/2 of the next scheduled dose at the end of hemodialysis.

If >3 hours since last fomepizole dose: Administer the next scheduled dose at the end of hemodialysis.

Maintenance dose off hemodialysis: Administer every 12 hours starting from the time last dose administered.

Dosing: Hepatic Impairment: Pediatric

Fomepizole is metabolized in the liver. Specific dosage adjustments have not been determined in patients with hepatic impairment.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Central nervous system: Headache (14%)

Gastrointestinal: Nausea (11%)

1% to 10% (≤3% unless otherwise noted):

Cardiovascular: Bradycardia, facial flushing, hypotension, phlebitis, shock, tachycardia

Central nervous system: Dizziness (6%), drowsiness (6%), metallic taste (≤6%), agitation, altered sense of smell, anxiety, seizure, speech disturbance, vertigo

Dermatologic: Skin rash

Gastrointestinal: Unpleasant taste (≤6%), abdominal pain, decreased appetite, diarrhea, heartburn, hiccups, vomiting

Genitourinary: Anuria

Hematologic & oncologic: Anemia, disseminated intravascular coagulation (DIC), eosinophilia, lymphangitis

Hepatic: Increased liver enzymes

Local: Application site reaction, inflammation at injection site, pain at injection site

Neuromuscular & skeletal: Back pain

Ophthalmic: Nystagmus, transient blurred vision, visual disturbance

Respiratory: Pharyngitis

Miscellaneous: Fever, multi-organ failure

<1%, postmarketing and/or case reports: Hypersensitivity reaction (mild; mild rash, eosinophilia)

Contraindications

Hypersensitivity to fomepizole, other pyrazoles, or any component of the formulation

Warnings/Precautions

Disease-related concerns:

• Hepatic impairment: Use with caution in patients with hepatic impairment; metabolized in the liver.

• Renal impairment: Use with caution in patients with renal impairment; fomepizole and its metabolites are excreted in the urine. Hemodialysis should be considered as an adjunct to fomepizole in patients with renal failure, significant acidosis (pH <7.25 to 7.3), worsening metabolic acidosis, or ethylene glycol or methanol concentrations ≥50 mg/dL.

• Isopropanol (isopropyl alcohol) poisoning: Fomepizole should not be administered in known isopropanol ingestions as the toxicity of isopropanol is predominantly due to the parent alcohol; inhibiting the metabolism of isopropanol may result in prolonged CNS depression, hypotension, or respiratory depression (Bekka 2001; Kraut 2018).

Other warnings/precautions:

• Administration: Should not be given undiluted or by bolus injection. Avoid using polycarbonate syringes or polycarbonate-containing needles (including polycarbonate filter needles) during dilution or administration; fomepizole may interfere with the integrity of polycarbonate products.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous [preservative free]:

Generic: 1.5 g/1.5 mL (1.5 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Antizol Intravenous)

1 g/mL (per mL): $1,233.20

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Antizol: 1 g/mL (1.5 mL)

Generic: 1 g/mL (1.5 mL)

Administration: Adult

IV: All doses should be administered as a slow IV infusion (IVPB) over 30 minutes. Avoid using polycarbonate syringes or polycarbonate-containing needles (including polycarbonate filter needles) during administration.

Administration: Pediatric

Parenteral: IV: Infuse as a diluted solution over 30 minutes; rapid infusion at a concentration of 25 mg/mL has been associated with vein irritation and phlebosclerosis. Avoid using polycarbonate syringes or polycarbonate-containing needles (including polycarbonate filter needles) during administration.

Use: Labeled Indications

Ethylene glycol or methanol toxicity: Treatment of known or suspected methanol or ethylene glycol poisoning alone or in combination with hemodialysis.

Note: Fomepizole is the preferred antidote for known or suspected ethylene glycol poisoning or methanol poisoning. If fomepizole is unavailable or if the patient is intolerant to fomepizole, ethanol therapy may be considered. Ethanol as an antidote is effective in the management of methanol and ethylene glycol poisoning (Thanacoody 2016; Zakharov 2015); however, ethanol is associated with a higher incidence of adverse events and medication errors (Bestic 2009; Lepik 2009; Lepik 2011).

Use: Off-Label: Adult

Acetaminophen overdose (adjunctive agent)

Medication Safety Issues
Sound-alike/look-alike issues:

Fomepizole may be confused with omeprazole

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003).

Breastfeeding Considerations

It is not known if fomepizole is excreted in breast milk. The manufacturer recommends that caution be exercised when administering fomepizole to nursing women.

Monitoring Parameters

Ideally, fomepizole plasma concentrations should be monitored; however, fomepizole concentrations are generally not available.

Use these parameters to monitor the response to fomepizole: Plasma (preferred)/urinary ethylene glycol or methanol concentrations, urinary oxalate (ethylene glycol), plasma (preferred)/urinary osmolality, renal/hepatic function, serum electrolytes, arterial blood gases; anion and osmolar gaps, resolution of clinical signs and symptoms of ethylene glycol or methanol intoxication

Reference Range

The manufacturer recommends concentrations concentrations of 8.2 to 24.6 mg/L (SI: 100 to 300 micromole/L) to achieve enzyme inhibition of alcohol dehydrogenase; according to practice guidelines, serum fomepizole concentrations of ≥0.8 mg//L (SI: 10 micromole/L) provide constant inhibition of alcohol dehydrogenase (Barceloux 1999; Barceloux 2002). However, fomepizole concentrations are generally not available.

Mechanism of Action

Fomepizole competitively inhibits alcohol dehydrogenase, an enzyme which catalyzes the metabolism of ethanol, ethylene glycol, and methanol to their toxic metabolites. Ethylene glycol is metabolized to glycoaldehyde, then oxidized to glycolate, glyoxylate, and oxalate. Glycolate and oxalate are responsible for metabolic acidosis and renal damage. Methanol is metabolized to formaldehyde, then oxidized to formic acid. Formic acid is responsible for metabolic acidosis and visual disturbances.

When used as adjunctive treatment for acetaminophen overdose, fomepizole is theorized to be protective during the injury phase as well as promote hepatocyte regeneration (Akakpo 2021; Akakpo 2022; Kang 2020). Fomepizole, via CYP2E1 inhibition, may attenuate the formation of N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite of acetaminophen that contributes to hepatocellular injury (Akakpo 2018; Kang 2020). In addition, fomepizole may inhibit c-Jun N-terminal kinase, thereby preventing amplification of mitochondrial damage by limiting mitochondrial oxidant stress and hepatocellular death after NAPQI has already been generated (Akakpo 2018; Akakpo 2019).

Pharmacokinetics (Adult Data Unless Noted)

Onset of effect: Peak effect: Maximum: 1.5 to 2 hours.

Absorption: Oral: Readily absorbed.

Distribution: Vd: 0.6 to 1.02 L/kg; rapidly into total body water.

Protein binding: Negligible.

Metabolism: Hepatic to 4-carboxypyrazole (80% to 85% of dose), 4-hydroxymethylpyrazole, and their N-glucuronide conjugates; following multiple doses, induces its own metabolism via CYP oxidases after 30 to 40 hours.

Half-life elimination: Varies with dose and duration. After 96 hours of administration, the self-induction of fomepizole metabolism results in a shortened half-life of 1.5 to 2 hours (McMartin 2012).

Excretion: Urine (1% to 3.5% as unchanged drug and metabolites).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AU) Australia: Antizol;
  • (CZ) Czech Republic: Fomepizole serb;
  • (DE) Germany: Fomepizole eusa pharma;
  • (EE) Estonia: Fomepizole eusa pharma | Fomepizole serb;
  • (FI) Finland: Fomepizole opi;
  • (GB) United Kingdom: Antizol;
  • (GR) Greece: Fomepizole eusa pharma | Fomepizole opi/france;
  • (IE) Ireland: Antizol | Fomepizole eusa pharma;
  • (NL) Netherlands: Fomepizole eusa pharma;
  • (NO) Norway: Fomepizole serb;
  • (NZ) New Zealand: Antizol;
  • (PR) Puerto Rico: Antizol;
  • (SE) Sweden: Fomepizole eusa pharma;
  • (SI) Slovenia: Fomepizole eusa pharma | Fomepizole serb;
  • (TW) Taiwan: Fomeject
  1. Akakpo JY, Ramachandran A, Curry SC, Rumack BH, Jaeschke H. Comparing N-acetylcysteine and 4-methylpyrazole as antidotes for acetaminophen overdose. Arch Toxicol. 2022;96(2):453-465. doi:10.1007/s00204-021-03211-z [PubMed 34978586]
  2. Akakpo JY, Jaeschke MW, Ramachandran A, Curry SC, Rumack BH, Jaeschke H. Delayed administration of N-acetylcysteine blunts recovery after an acetaminophen overdose unlike 4-methylpyrazole. Arch Toxicol. 2021;95(10):3377-3391. doi:10.1007/s00204-021-03142-9 [PubMed 34420083]
  3. Akakpo JY, Ramachandran A, Duan L, et al. Delayed treatment with 4-methylpyrazole protects against acetaminophen hepatotoxicity in mice by inhibition of c-Jun N-terminal kinase. Toxicol Sci. 2019;170(1):57-68. doi:10.1093/toxsci/kfz077 [PubMed 30903181]
  4. Akakpo JY, Ramachandran A, Kandel SE, et al. 4-methylpyrazole protects against acetaminophen hepatotoxicity in mice and in primary human hepatocytes. Hum Exp Toxicol. 2018;37(12):1310-1322. doi:10.1177/0960327118774902 [PubMed 29739258]
  5. Akakpo JY, Ramachandran A, Orhan H, Curry SC, Rumack BH, Jaeschke H. 4-methylpyrazole protects against acetaminophen-induced acute kidney injury. Toxicol Appl Pharmacol. 2020;409:115317. doi:10.1016/j.taap.2020.115317 [PubMed 33157119]
  6. Antizol (fomepizole injection) [prescribing information]. Dover, DE: Paladin Labs (USA) Inc; December 2020.
  7. Antizol (fomepizole) [product monograph]. St-Laurent, Quebec, Canada: Paladin Labs Inc; October 2017.
  8. Bailey B. Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women? Birth Defects Res A Clin Mol Teratol. 2003;67(2):133-140. [PubMed 12769509]
  9. Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning. J Toxicol Clin Toxicol. 2002;40(4):415-446. [PubMed 12216995]
  10. Barceloux DG, Krenzelok EP, Olson K, et al. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. J Toxicol Clin Toxicol. 1999;37(5):537-560. [PubMed 10497633]
  11. Battistella M. Fomepizole as an Antidote for Ethylene Glycol Poisoning. Ann Pharmacother. 2002;36(6):1085-1089. [PubMed 12022913]
  12. Baum CR, Langman CB, Oker EE, et al. Fomepizole Treatment of Ethylene Glycol Poisoning in an Infant. Pediatrics. 2000;106(6):1489-1491. [PubMed 11099610]
  13. Bekka R, Borron SW, Astier A, Sandouk P, Bismuth C, Baud FJ. Treatment of methanol and isopropanol poisoning with intravenous fomepizole. J Toxicol Clin Toxicol. 2001;39(1):59-67.
  14. Benitez JG, Swanson-Biearman B, Krenzelok EP. Nystagmus Secondary to Fomepizole Administration in a Pediatric Patient. J Toxicol Clin Toxicol. 2000;38(7):795-798. [PubMed 11192468]
  15. Bestic M, Blackford M, Reed M. Fomepizole: a critical assessment of current dosing recommendations. J Clin Pharmacol. 2009;49(2):130-137. [PubMed 19004845]
  16. Borron SW, Baud FJ. Intravenous 4-Methylpyrazole as an Antidote for Diethylene Glycol and Triethylene Glycol Poisoning: A Case Report. Vet Hum Toxicol. 1997;37(1):26-28.
  17. Boyer EW, Mejia M, Woolf A, et al. Severe Ethylene Glycol Ingestion Treated Without Hemodialysis. Pediatrics. 2001;107(1):172-173. [PubMed 11134452]
  18. Brent J. Fomepizole for the treatment of pediatric ethylene and diethylene glycol, butoxyethanol, and methanol poisonings. Clin Toxicol (Phila). 2010;48(5):401-406. [PubMed 20586570]
  19. Brent J, McMartin K, Phillips S, et al. 4-Methylpyrazole (Fomepizole) Therapy of Ethylene Glycol Poisoning: Preliminary Results of the Meta Trial. J Toxicol Clin Toxicol. 1997;35(5):507.
  20. Brent J, McMartin K, Phillips S, et al. Fomepizole for the Treatment of Methanol Poisoning. N Engl J Med. 2001;344(6):424-429. [PubMed 11172179]
  21. Brent J, McMartin K, Phillips S, et al; Methylpyrazole for Toxic Alcohols Study Group. Fomepizole for the treatment of ethylene glycol poisoning. N Engl J Med. 1999;340(11):832-838. doi:10.1056/NEJM199903183401102 [PubMed 10080845]
  22. Brown MJ, Shannon MW, Woolf A, et al. Childhood Methanol Ingestion Treated With Fomepizole and Hemodialysis. Pediatrics. 2001;108(4):e77-e79. [PubMed 11581485]
  23. Calello DP, Osterhoudt KC, Henretig FM. New and novel antidotes in pediatrics. Pediatr Emerg Care. 2006;22(7):523-530. Erratum in intravenous n-acetylcysteine dosing [Pediatr Emerg Care. 2007]. [PubMed 16871118]
  24. Casavant MJ. Fomepizole in the treatment of poisoning. Pediatrics. 2001;107(1):170. [PubMed 11134450]
  25. Chen TH, Kuo CH, Huang CT, Wang WL. Use of fomepizole in pediatric methanol exposure: the first case report in Taiwan and a literature review. Pediatr Neonatol. 2016;57(4):351-354 [PubMed 24332660]
  26. Chiu MH, Jaworska N, Li NL, Yarema M. Massive acetaminophen overdose treated successfully with N-acetylcysteine, fomepizole, and hemodialysis. Case Rep Crit Care. 2021;2021:6695967. doi:10.1155/2021/6695967 [PubMed 34336301]
  27. Dart RC, Goldfrank LR, Chyka PA, et al. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med. 2000;36(2):126-132. [PubMed 10918103]
  28. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021 [PubMed 28669553]
  29. Dart RC, Mullins ME, Matoushek T, et al. Management of acetaminophen poisoning in the US and Canada: A consensus statement. JAMA Netw Open. 2023;6(8):e2327739. doi:10.1001/jamanetworkopen.2023.27739 [PubMed 37552484]
  30. De Brabander N, Wojciechowski M, De Decker K, et al. Fomepizole as a Therapeutic Strategy in Paediatric Methanol Poisoning: A Case Report and Review of the Literature. Eur J Pediatr. 2005;164(3):158-161. [PubMed 15578220]
  31. Detaille T, Wallemacq P, Clement de Clety S, et al. Fomepizole Alone for Severe Infant Ethylene Glycol Poisoning. Pediatr Crit Care Med. 2004;5(5):490-491. [PubMed 15329167]
  32. Druteika DP, Zed PJ, Ensom MH. Role of Fomepizole in the Management of Ethylene Glycol Toxicity. Pharmacotherapy. 2002;22(3):365-372. [PubMed 11899949]
  33. Fisher DM, Diaz JE. Pediatric Methanol Poisoning Treated With Fomepizole (Antizol®). J Toxicol Clin Toxicol. 1998;36:512.
  34. Hann G, Duncan D, Sudhir G, West P, Sohi D. Antifreeze on a freezing morning: ethylene glycol poisoning in a 2-year-old. BMJ Case Rep. 2012;27:2012 [PubMed 22605809]
  35. Hung O, Kaplan J, Hoffman R, et al. Improved Understanding of the Ethanol-Chloral Hydrate Interaction Using 4-MP. J Toxicol Clin Toxicol. 1997;35(5):507-508.
  36. Jacobsen D, McMartin KE. 4-Methylpyrazole - Present Status. J Toxicol Clin Toxicol. 1996;34(4):379-381. [PubMed 8699551]
  37. Jacobsen D, McMartin KE. Antidotes for Methanol and Ethylene Glycol Poisoning. J Toxicol Clin Toxicol. 1997;35(2):127-143. [PubMed 9120880]
  38. Jacobsen D, Ostensen J, Bredesen L, et al. 4-Methylpyrazole (4-MP) Is Effectively Removed by Haemodialysis in the Pig Model. Hum Exp Toxicol. 1996;15(6):494-496. [PubMed 8793532]
  39. Jacobsen D, Sebastian CS, Barron SK, et al. Effects of 4-Methylpyrazole, Methanol/Ethylene Glycol Antidote in Healthy Humans. J Emerg Med. 1990;8(4):455-461. [PubMed 2212566]
  40. Jobard E, Harry P, Turcant A, et al. 4-Methylpyrazole and Hemodialysis in Ethylene Glycol Poisoning. J Toxicol Clin Toxicol. 1996;34(4):373-377. [PubMed 8699550]
  41. Kang AM, Padilla-Jones A, Fisher ES, et al. The effect of 4-methylpyrazole on oxidative metabolism of acetaminophen in human volunteers. J Med Toxicol. 2020;16(2):169-176. doi:10.1007/s13181-019-00740-z [PubMed 31768936]
  42. Kiernan EA, Fritzges JA, Henry KA, Katz KD. A case report of massive acetaminophen poisoning treated with a novel "triple therapy": N-acetylcysteine, 4-methylpyrazole, and hemodialysis. Case Rep Emerg Med. 2019;2019:9301432. doi:10.1155/2019/9301432 [PubMed 30956824]
  43. Kraut JA, Mullins ME. Toxic alcohols. N Engl J Med. 2018;378(3):270-280. doi:10.1056/NEJMra1615295 [PubMed 29342392]
  44. Lao YE, Vartdal T, Froeyshov S, et al. Fomepizole dosing during continuous renal replacement therapy - an observational study. Clin Toxicol (Phila). 2022;60(4):451-457. doi:10.1080/15563650.2021.1980581 [PubMed 34585641]
  45. Lepik KJ, Levy AR, Sobolev BG, et al. Adverse drug events associated with the antidotes for methanol and ethylene glycol poisoning: a comparison of ethanol and fomepizole. Ann Emerg Med. 2009;53(4):439-450. [PubMed 18639955]
  46. Lepik KJ, Sobolev BG, Levy AR, et al. Medication errors associated with the use of ethanol and fomepizole as antidotes for methanol and ethylene glycol poisoning. Clin Toxicol (Phila). 2011;49(5):391-401. [PubMed 21740138]
  47. Link SL, Rampon G, Osmon S, Scalzo AJ, Rumack BH. Fomepizole as an adjunct in acetylcysteine treated acetaminophen overdose patients: a case series. Clin Toxicol (Phila). 2022;60(4):472-477. doi:10.1080/15563650.2021.1996591 [PubMed 34709101]
  48. McMartin K, Jacobsen D, Hovda KE. Antidotes for poisoning by alcohols that form toxic metabolites. Br J Clin Pharmacol. 2016;81(3):505-515. doi:10.1111/bcp.12824 [PubMed 26551875]
  49. McMartin KE, Heath A. Treatment of Ethylene Glycol Poisoning With Intravenous 4-Methylpyrazole. N Engl J Med. 1989;320(2):125. [PubMed 2911289]
  50. McMartin KE, Sebastian CS, Dies D, Jacobsen D. Kinetics and metabolism of fomepizole in healthy humans. Clin Toxicol. 2012;50(5):375-383. [PubMed 22554311]
  51. Mokhlesi B, Leikin JB, Murray P, et al. Adult Toxicology in Critical Care: Part II: Specific Poisonings. Chest. 2003;123(3):897-922. [PubMed 12628894]
  52. Pepin L, Matsler N, Fontes A, Heard K, Flaherty BF, Monte AA. Fomepizole therapy for acetaminophen-induced liver failure in an infant. Pediatrics. 2023;152(4):e2022061033. doi:10.1542/peds.2022-061033 [PubMed 37681263]
  53. Pourbagher-Shahri AM, Schimmel J, Shirazi FM, Nakhaee S, Mehrpour O. Use of fomepizole (4-methylpyrazole) for acetaminophen poisoning: a scoping review. Toxicol Lett. 2022;355:47-61. doi:10.1016/j.toxlet.2021.11.005 [PubMed 34785186]
  54. Rampon G, Wartman H, Osmon S, Scalzo A. Use of fomepizole as an adjunct in the treatment of acetaminophen overdose: a case series. Toxicology Communications. 2020;4(1):1-4. https://www.tandfonline.com/loi/ttxc20. doi:10.1080/24734306.2019.1705596
  55. Roberts DM, Yates C, Megarbane B, et al. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. Crit Care Med. 2015;43(2):461-472. [PubMed 25493973]
  56. Shah KR, Beuhler MC. Fomepizole as an adjunctive treatment in severe acetaminophen toxicity. Am J Emerg Med. 2020;38(2):410.e5-410.e6. doi:10.1016/j.ajem.2019.09.005 [PubMed 31785979]
  57. Shah KR, Fox C, Geib AJ, et al. Fomepizole as an adjunctive treatment in severe acetaminophen ingestions: a case series. Clin Toxicol (Phila). 2021;59(1):71-72. doi:10.1080/15563650.2020.1775847 [PubMed 32538692]
  58. Thanacoody RH, Gilfillan C, Bradberry SM, et al. Management of poisoning with ethylene glycol and methanol in the UK: a prospective study conducted by the National Poisons Information Service (NPIS). Clin Toxicol (Phila). 2016;54(2):134-140. [PubMed 26594941]
  59. Wang GS, Yin S, Shear B, Heard K. Severe poisoning after accidental pediatric ingestion of glycol ethers. Pediatrics. 2012;130(4):e1026-1029. [PubMed 23008459]
  60. White ML, Liebelt EL. Update on antidotes for pediatric poisoning. Pediatr Emerg Care. 2006;22(11):740-746. [PubMed 17110870]
  61. Woolum JA, Hays WB, Patel KH. Use of fomepizole, n-acetylcysteine, and hemodialysis for massive acetaminophen overdose. Am J Emerg Med. 2020;38(3):692.e5-692.e7. doi:10.1016/j.ajem.2019.09.026 [PubMed 31785980]
  62. Zakharov S, Pelclova D, Navratil T, et al. Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak. Clin Toxicol (Phila). 2015;53(8):797-806. [PubMed 26109326]
Topic 8633 Version 163.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟